Antimalarials, aminoquinolines
ATC code: P01BA02 (Hydroxychloroquine)
Brand names
Plaquenil
Chloroquine derivative with a better safety profile. Accumulates in lysosomes, raises their pH, and disrupts macrophage, dendritic cell, T- and B-lymphocyte function. Suppresses toll-like receptors 7 and 9, reducing type I interferon production — a key mechanism in SLE. Effect develops over 3–6 months. The narrow window is not about efficacy but about retinopathy prevention — maximum 5 mg/kg ideal body weight per day.
First line
Foundation therapy for all SLE patients regardless of severity per 2023, 2024, BSR 2018. Reduces flare frequency, organ damage, thromboembolic events, and all-cause mortality — the only drug with demonstrated benefit on long-term SLE outcomes. Dose 200–400 mg/day, not exceeding 5 mg/kg ideal body weight to prevent retinopathy. Effect develops over 3–6 months. Ophthalmologic exam at baseline, after 5 years, then annually.
Second line
Per 2023, hydroxychloroquine is used in mild rheumatoid arthritis or as part of combination therapy. Structural disease-modifying effect is weaker than methotrexate, so it is not first choice in active disease.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Hydroxychloroquine is an antimalarial and disease-modifying antirheumatic drug. It is prescribed for systemic lupus erythematosus, rheumatoid arthritis, discoid lupus erythematosus, and for malaria prevention and treatment ( 2023, 2020 guidelines). In anti-aging communities, low-dose hydroxychloroquine is positioned as an anti-aging and life-extension agent. In healthy adults, no clinical studies of such use exist; international anti-aging guidelines do not include hydroxychloroquine. The drug has serious risks on long-term use: irreversible retinopathy (with vision loss risk, requires ophthalmologic screening every 6-12 months), cardiomyopathy, myopathy, neuropathy, and QT prolongation. If hydroxychloroquine was recommended to a healthy person for anti-aging, consider seeking a second opinion.
Not recommended
Hydroxychloroquine is an antimalarial and disease-modifying antirheumatic drug. It is prescribed for systemic lupus erythematosus, rheumatoid arthritis, discoid lupus erythematosus, and for malaria prevention and treatment ( 2023, 2020). In 2020 hydroxychloroquine was actively promoted as a COVID-19 treatment and prophylaxis. The RECOVERY (NEJM 2020) and Solidarity ( 2020) trials in tens of thousands of patients showed no benefit and a signal of increased mortality in hospitalized COVID-19 patients. WHO Living Guideline 2023 and NIH COVID-19 Guidelines 2024 strongly advise against hydroxychloroquine for COVID-19. The drug has serious risks on long-term use: irreversible retinopathy with vision-loss risk, QT prolongation, and cardiomyopathy. If hydroxychloroquine was recommended for COVID-19 or for immunity, consider seeking a second opinion.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Use in pregnant SLE patients is mandatory — discontinuation is associated with disease flares and adverse pregnancy outcomes. Pregnancy registries show no increased malformation risk.
Transfers into milk in small amounts. Compatible with breastfeeding per LactMed.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Hydroxychloroquine is evaluated for the following indications with varying evidence strength: Systemic lupus erythematosus (evidence tier A), Rheumatoid arthritis (evidence tier B), Immune support and respiratory infection care (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of Hydroxychloroquine (≥ 1 in 100): Dyspepsia, nausea, diarrhea, Skin rash, pruritus, Headache, Skin and mucosal hyperpigmentation (reversible). See the Safety section for uncommon and serious reactions.
FDA category C. Use in pregnant SLE patients is mandatory — discontinuation is associated with disease flares and adverse pregnancy outcomes. Pregnancy registries show no increased malformation risk.
Transfers into milk in small amounts. Compatible with breastfeeding per LactMed.
Hydroxychloroquine is contraindicated in: Known retinopathy; G6PD deficiency; Severe hematological disease; Hypersensitivity to 4-aminoquinolines. Full list in the Safety section.